Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Item
http://www.wikidata.org/entity/Q38562354
Chronic myeloid leukemia: reminiscences and dreamsCurrent developments in molecular monitoring in chronic myeloid leukemiaThe impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors.Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.Development of a protease-resistant reporter to quantify BCR-ABL activity in intact cells.Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults.BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib.Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.Another tyrosine kinase inhibitor-resistance mutation within the BCR-ABL kinase domain: chasing our tails?Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy.
P2860

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Item
http://www.wikidata.org/entity/Q38562354
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Compound mutations in BCR-ABL1 ...... ponatinib in CP-CML patients.
@en
type
label
Compound mutations in BCR-ABL1 ...... ponatinib in CP-CML patients.
@en
prefLabel
Compound mutations in BCR-ABL1 ...... ponatinib in CP-CML patients.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
Compound mutations in BCR-ABL1 ...... ponatinib in CP-CML patients.
@en
P2093
P2860
P304
P31
P356
10.1182/BLOOD-2015-08-660977
P407
P433
P478
P50
P577
P698
P932